Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02323113
Title Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35233 United States Details
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago Illinois 60611 United States Details
Oncology Specialists, S.C. Niles Illinois 60714 United States Details
Johns Hopkins Hospital Baltimore Maryland 21287 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 United States Details
Karmanos Cancer Center Detroit Michigan 48201 United States Details
Henry Ford Health System Detroit Michigan 48202 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
North Shore Long Island Jewish Medical Center New York New York 10024 United States Details
University of North Carolina Hospital Chapel Hill North Carolina 27514 United States Details
UC Health Clinical Trials Office Cincinnati Ohio 45206 United States Details
Baylor University Medical Center Dallas Texas 75204 United States Details
Medical College of Wisconsin, Inc. Milwaukee Wisconsin 53266 United States Details
Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia B3H 3A7 Canada Details
Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
Wake Forest University Baptist Medical Center Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from for the field